166. Pseudoxanthoma elasticum Clinical trials / Disease details


Clinical trials : 16 Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04868578
(ClinicalTrials.gov)
December 13, 202230/3/2021PPI Supplementation to Fight ECtopIc Calcification in PXEEfficacy of PyROphosPHate Supplementation to Fight ECtopIc Calcification in PseudoXanthoma Elasticum - PROPHECI-PPI StudyPseudoxanthoma ElasticumDietary Supplement: study treatment PPI;Dietary Supplement: Placebo comparatorCentre Hospitalier Universitaire de NiceNULLRecruiting18 Years65 YearsAll99N/AFrance
2NCT05569252
(ClinicalTrials.gov)
October 20, 20224/10/2022A Study of DS-1211b in Individuals With PseudoXanthoma ElasticumA Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma ElasticumPseudoxanthoma ElasticumDrug: DS-1211b;Other: PlaceboDaiichi Sankyo, Inc.PXE InternationalRecruiting18 Years75 YearsAll64Phase 2United States;Netherlands
3NCT05030831
(ClinicalTrials.gov)
April 11, 202226/8/2021Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXEA Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)ATP-Binding Cassette Subfamily C Member 6 Deficiency;Pseudoxanthoma Elasticum;Generalized Arterial Calcification of InfancyDrug: INZ-701Inozyme PharmaIQVIA BiotechRecruiting18 Years69 YearsAll9Phase 1/Phase 2United States;United Kingdom
4EUCTR2020-004000-33-FR
(EUCTR)
10/06/202128/04/2021A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of INZ-701 in Adults with ABCC6 Deficiency causing Pseudoxanthoma elasticum (PXE)A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE) Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: INZ-701
Product Code: INZ-701
INN or Proposed INN: RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
Other descriptive name: RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
Inozyme Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
9Phase 1;Phase 2France
5NCT04441671
(ClinicalTrials.gov)
December 8, 202020/1/2020Oral Pyrophosphate Absorption in PXE DiseaseOral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: Disodium PyrophosphateTampere University HospitalUMC Utrecht;Hungarian Academy of SciencesWithdrawn18 Years80 YearsAll0Phase 2NULL
6NCT04660461
(ClinicalTrials.gov)
February 4, 20203/12/2020Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Drug: Lansoprazole 30mg;Drug: PlaceboFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNULLRecruiting18 YearsN/AAll20Phase 4Spain
7EUCTR2019-002109-24-FI
(EUCTR)
01/08/201901/07/2019Oral Pyrophosphate Absorption in PXE DiseaseOral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum - Oral Pyrophosphate Absorption in PXE Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Product Name: DisodiumpyrophosphateTampere University HospitalNULLNot RecruitingFemale: yes
Male: yes
10Phase 2Finland
8EUCTR2016-004021-16-ES
(EUCTR)
31/10/201810/03/2017Response to oral lansoprazole in patients with Pseudoxanthoma ElasticumResponse to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - FIM-PXE-2016-01 Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
MedDRA version: 19.1;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Lansoprazole
INN or Proposed INN: Lansolprazole
Other descriptive name: LANSOPRAZOLE
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Spain
9EUCTR2018-001492-20-FI
(EUCTR)
20/06/201811/06/2018Pyrophosphate therapy in PXE diseasePseudoxanthoma elasticum – supplementation therapy of pyrophosphate deficiency Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SODIUM ACID PYROPHOSPHATE
Product Name: SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE
Product Code: CAS No.: 7758-16-9
Tampere university hospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2;Phase 3Finland
10NCT02537054
(ClinicalTrials.gov)
September 201521/8/2015Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: AfliberceptUniversity Hospital, BonnNULLCompleted18 Years65 YearsAll15Phase 2Germany
11EUCTR2014-005263-33-DE
(EUCTR)
29/04/201526/02/2015Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumIntravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: EyleaMedizinische Fakultät der Universität BonnNULLNot RecruitingFemale: yes
Male: yes
15Phase 2Germany
12EUCTR2013-001421-55-FR
(EUCTR)
13/06/201322/09/2015An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEAn open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSE Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy
MedDRA version: 18.0;Level: HLGT;Classification code 10047060;Term: Retina, choroid and vitreous haemorrhages and vascular disorders;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002A
INN or Proposed INN: RANIBIZUMAB
Novartis Pharma S.A.SNULLNot RecruitingFemale: yes
Male: yes
500Phase 3France
13NCT01525875
(ClinicalTrials.gov)
August 20121/2/2012Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: Magnesium Oxide;Drug: PlaceboMark LebwohlNULLCompleted18 YearsN/AAll44Phase 2United States
14NCT00510965
(ClinicalTrials.gov)
August 20071/8/2007Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)Choroidal NeovascularizationDrug: Intravitreal injection ranibizumabUniversity Hospital, BonnNovartisCompleted18 Years65 YearsBoth10Phase 2Germany
15EUCTR2006-006231-49-DE
(EUCTR)
24/07/200706/03/2007Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease
MedDRA version: 8.1;Level: LLT;Classification code 10037150;Term: Pseudoxanthoma elasticum
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002
INN or Proposed INN: ranibizumab
Other descriptive name: RFB002, rhuFab V2
Department of Ophthalmology, Bonn UniversityNULLNot RecruitingFemale: yes
Male: yes
10Phase 2Germany
16NCT00470977
(ClinicalTrials.gov)
May 20074/5/2007Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related MaculopathyTreatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)Coats' Disease;Idiopathic Retinal Telangiectasia;Retinal Angiomatous Proliferation;Polypoidal Choroidal Vasculopathy;Pseudoxanthoma Elasticum;Pathological Myopia;Multi-focal Choroiditis;Rubeosis Iridis;Von Hippel Lindau Disease;BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)Drug: ranibizumab injection (0.5 mg)Manhattan Eye, Ear & Throat HospitalGenentech, Inc.Completed18 YearsN/ABoth18Phase 1/Phase 2United States